Long-acting Medications for HepC in Low- and Middle-Income Countries: Survey for HepC Providers and Policymakers
The Coalition for Global Hepatitis Elimination (CGHE) is releasing a new survey to understand provider and policymaker perspectives on how long-acting HCV medications could improve patient HCV treatment access and outcomes, on any concerns regarding long-acting HCV medications, and preferences for the type of long-acting HCV formulations that would be most feasible to implement in clinical practice.
“Long-acting” medications refer to formulations of medications that prolong the patient’s exposure to the effect of the medication over a longer period of time, with the potential to drastically reduce the number of times a patient takes a medication. These medications can be administered through different routes, such as injections, implants, patches, or other technologies. Long-acting medications have been developed and commonly used to improve adherence and treatment outcomes for conditions such as HIV and psychosis.
There are currently several long-acting formulations under development using existing oral medications for the treatment of Hepatitis C Virus (HCV). This work is being conducted as part of the LONGEVITY project, funded by UNITAID, specifically targeting implementation in low- and middle-income countries (LMICs). As part of the development of these medications, it is essential to consider the preferences and perceptions of clinical providers involved in the treatment of HCV in these settings.
This survey will be open to policymakers and clinical providers that prescribe medication for the treatment of HCV in LMICs. It is available in English, Spanish, French and Portuguese. The total estimated time for the survey is 10 minutes.
The survey can be found at the link below, and will be open beginning Nov 22, 2022.
Complete the survey here: https://redcap.emory.edu/surveys/?s=9WEL8K9EEM4WW9WP
The results of the survey will be used by the Coalition to determine provider interest, concerns and capacity regarding long-acting medications for the treatment of patients with hepatitis C. For any questions/additional comments regarding the survey, please contact:
Chief Technical Officer
Coalition for Global Hepatitis Elimination
ngupta-consultant [at] taskforce.org